 GAITHERSBURG, Md., Aug. 25, 2021 GLOBE NEWSWIRE -- Emergent BioSolutions Inc. NYSE:EBS today announced the initiation of a Phase 3 clinical trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous Human COVID-HIG plasma-derived therapy as a potential outpatient treatment for patients with coronavirus disease COVID-19 that are at high risk of progression to severe disease, including adults 55 and older and those 18 and older who are immunocompromised. 